EE05431B1 - Metalloproteinaasi inhibiitorid - Google Patents

Metalloproteinaasi inhibiitorid

Info

Publication number
EE05431B1
EE05431B1 EEP200300445A EEP200300445A EE05431B1 EE 05431 B1 EE05431 B1 EE 05431B1 EE P200300445 A EEP200300445 A EE P200300445A EE P200300445 A EEP200300445 A EE P200300445A EE 05431 B1 EE05431 B1 EE 05431B1
Authority
EE
Estonia
Prior art keywords
metalloproteinase inhibitors
metalloproteinase
inhibitors
Prior art date
Application number
EEP200300445A
Other languages
English (en)
Inventor
Eriksson Anders
Lepist Matti
Lundkvist Michael
Munck Af Rosenschld Magnus
Zlatoidsky Pavol
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300445A publication Critical patent/EE200300445A/et
Publication of EE05431B1 publication Critical patent/EE05431B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
EEP200300445A 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid EE05431B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0100902A SE0100902D0 (sv) 2001-03-15 2001-03-15 Compounds
PCT/SE2002/000472 WO2002074767A1 (en) 2001-03-15 2002-03-13 Metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
EE200300445A EE200300445A (et) 2003-12-15
EE05431B1 true EE05431B1 (et) 2011-06-15

Family

ID=20283374

Family Applications (3)

Application Number Title Priority Date Filing Date
EEP200300445A EE05431B1 (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
EEP200300451A EE05364B1 (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
EEP200300449A EE200300449A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid

Family Applications After (2)

Application Number Title Priority Date Filing Date
EEP200300451A EE05364B1 (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid
EEP200300449A EE200300449A (et) 2001-03-15 2002-03-13 Metalloproteinaasi inhibiitorid

Country Status (33)

Country Link
US (8) US7368465B2 (et)
EP (4) EP1370537B1 (et)
JP (4) JP4390457B2 (et)
KR (4) KR100879905B1 (et)
CN (5) CN100526307C (et)
AR (2) AR035443A1 (et)
AT (3) ATE493406T1 (et)
AU (2) AU2002237632B2 (et)
BR (3) BR0207984A (et)
CA (3) CA2440631A1 (et)
CY (1) CY1107525T1 (et)
CZ (3) CZ20032497A3 (et)
DE (3) DE60238794D1 (et)
DK (1) DK1370556T3 (et)
EE (3) EE05431B1 (et)
ES (3) ES2357138T3 (et)
HK (3) HK1091492A1 (et)
HU (3) HUP0400194A3 (et)
IL (5) IL157652A0 (et)
IS (3) IS6942A (et)
MX (3) MXPA03008191A (et)
MY (2) MY136141A (et)
NO (3) NO20034044L (et)
NZ (3) NZ528140A (et)
PL (3) PL365099A1 (et)
PT (1) PT1370556E (et)
RU (3) RU2293729C2 (et)
SE (1) SE0100902D0 (et)
SI (1) SI1370556T1 (et)
SK (3) SK287766B6 (et)
UA (3) UA77408C2 (et)
WO (3) WO2002074767A1 (et)
ZA (4) ZA200306732B (et)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
SE0202539D0 (sv) * 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202693D0 (sv) * 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
WO2004033632A2 (en) * 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
EP2426120A1 (en) 2003-08-18 2012-03-07 Fujifilm Finechemicals Co., Ltd. Pyridyltetrahydropyridines and pyridylpiperidines, and method of manufacturing them
WO2005090316A1 (en) * 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0401762D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
EP1802331A2 (en) * 2004-09-08 2007-07-04 Boys Town National Research Hospital Treatment of glomerular basement membrane disease involving matrix metalloproteinase-12
US7592343B2 (en) 2004-09-20 2009-09-22 Xenon Pharmaceuticals Inc. Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors
CA2580855A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
CN101083992A (zh) 2004-09-20 2007-12-05 泽农医药公司 抑制人硬脂酰CoA去饱和酶的哒嗪衍生物
TW200624427A (en) 2004-09-20 2006-07-16 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
TW200626592A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
CA2601076C (en) * 2005-03-16 2014-07-08 Advanced Metering Data Systems, L.L.C. Method, system, apparatus, and computer program product for determining a physical location of a sensor
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
PE20071241A1 (es) * 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200800954A (en) * 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
EP2024178B1 (en) * 2006-05-12 2013-01-09 SCA Hygiene Products AB Elastic laminate and a method for producing an elastic laminate
JP4987967B2 (ja) * 2006-05-12 2012-08-01 エスセーアー・ハイジーン・プロダクツ・アーベー パンツ型吸収用品およびパンツ型吸収用品を製造するための方法
WO2008053199A1 (en) * 2006-10-30 2008-05-08 Astrazeneca Ab Combination therapy for the treatment of respiratory diseases
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
CN101854898B (zh) 2007-11-14 2013-06-26 Sca卫生用品公司 制造吸收性衣物的方法和根据该方法制造的吸收性衣物
US20100262110A1 (en) 2007-11-14 2010-10-14 Sca Hygiene Products Ab Method of producing an absorbent garment, and an absorbent garment produced according to the method
FR2927330B1 (fr) * 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AU2009241365B2 (en) 2008-04-28 2015-01-22 Revalesio Corporation Compositions and methods for treating multiple sclerosis
FR2944524B1 (fr) * 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
ES2525353T3 (es) * 2009-04-28 2014-12-22 Chugai Seiyaku Kabushiki Kaisha Derivado de espiroimidazolona
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
CN102711991B (zh) * 2009-11-06 2015-01-21 巴斯夫欧洲公司 含铁和锰的非均相催化剂和通过一氧化碳与氢气反应而制备烯烃的方法
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
WO2011153359A1 (en) 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
CN103958480B (zh) * 2012-09-04 2016-04-06 上海恒瑞医药有限公司 咪唑啉类衍生物、其制备方法及其在医药上的应用
ES2663797T3 (es) 2012-12-10 2018-04-17 Chugai Seiyaku Kabushiki Kaisha Derivados de hidantoína
DK3068413T4 (da) * 2013-11-13 2023-08-14 Forchem Oy Fodersupplement omfattende resinsyre
JP6227149B2 (ja) * 2013-12-31 2017-11-08 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエＩｐｓｅｎ Ｐｈａｒｍａ Ｓ．Ａ．Ｓ． 新規のイミダゾリジン−２，４−ジオン誘導体
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
CN106572994B (zh) 2014-06-09 2020-09-18 中外制药株式会社 含有乙内酰脲衍生物的药物组合物
KR102134171B1 (ko) 2014-10-24 2020-07-15 란도스 바이오파마, 인크. 란티오닌 합성효소 c-유사 2-계 치료제
JO3501B1 (ar) 2014-12-22 2020-07-05 Servier Lab مشتقات 5-{(بيبرازين - 1-يل)-3-أوكسو - بروبيل}- إيميدازوليدين-2، 4 - دايون كمثبطات ل adamts لمعالجة هشاشة العظام)
CA3036642C (en) * 2016-09-23 2024-04-09 Kaken Pharmaceutical Co., Ltd. Method for producing (r)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2h)-yl)methyl]imidazolidin-2,4-dione and intermediate for producing same
WO2021011723A1 (en) * 2019-07-18 2021-01-21 Avidence Therapeutics, Inc. Anti-osteoarthritis hydantoin compounds and related compositions and methods
JP2023502093A (ja) * 2019-11-14 2023-01-20 フォアシー ファーマシューティカルズ カンパニー リミテッド マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法
KR20230026522A (ko) 2019-12-20 2023-02-24 란도스 바이오파마, 인크. 란티오닌 c-유사 단백질 2 리간드, 이로 제조된 세포, 및 이를 사용하는 치료법
WO2021260387A1 (en) 2020-06-26 2021-12-30 The University Of Birmingham Mmp-9 and mmp-12 inhibition for treating spinal cord injury or related injury to neurological tissue
WO2022007866A1 (zh) * 2020-07-09 2022-01-13 深圳信立泰药业股份有限公司 并三环类衍生物、其制备方法及其在医药上的应用
CN112574193B (zh) * 2020-12-31 2022-05-17 南京医科大学 一类口服gsnor抑制剂及其药物用途

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) * 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
CS152617B1 (et) 1970-12-29 1974-02-22
CS151744B1 (et) 1971-01-19 1973-11-19
US3849574A (en) * 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) * 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
JPH0279879A (ja) 1988-09-17 1990-03-20 Canon Inc 画像形成装置
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
JPH07105549A (ja) 1993-09-30 1995-04-21 Canon Inc 光学的情報記録再生方法及び光学的情報記録再生装置
JPH09505310A (ja) 1993-11-16 1997-05-27 メルク エンド カンパニー インコーポレーテッド ピペリジンショウノウスルホニルオキシトシン拮抗剤
RU2126404C1 (ru) 1994-01-31 1999-02-20 Пфайзер Инк. 3r*, 4s* -3-[4-(4-фторфенил-4-гидроксипиперидин-1-ил] хроман- 4,7-диол, его оптические изомеры и фармацевтическая композиция на его основе и способы лечения
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
WO1997019075A1 (en) * 1995-11-22 1997-05-29 Darwin Discovery Limited Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf)
GB9616643D0 (en) * 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) * 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
ATE212619T1 (de) 1996-10-22 2002-02-15 Upjohn Co Alpha-amino sulfonyl hydroxamsäure als matrix metalloproteinase inhibitoren
HUP0003362A3 (en) * 1997-05-06 2001-04-28 Novo Nordisk As Piperidine derivatives and pharmaceutical compositions containing them
DE59802394D1 (de) * 1997-05-09 2002-01-24 Hoechst Ag Substituierte Diaminocarbonsäuren
US6335332B1 (en) 1997-06-21 2002-01-01 Roche Diagnostics Gmbh Barbituric acid derivatives with antimetastatic and antitumor activity
DE19726427A1 (de) 1997-06-23 1998-12-24 Boehringer Mannheim Gmbh Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
TR199903287T2 (xx) 1997-07-31 2000-09-21 Abbott Laboratories Matriks metaloproteinazlar�n�n ters hidroksamat inhibit�rleri.
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
KR100609926B1 (ko) 1997-11-12 2006-08-04 다윈 디스커버리 리미티드 엠엠피와 티엔에프 억제 활성을 갖는 히드록삼산 및카르복실산 유도체
KR20010040698A (ko) 1998-02-04 2001-05-15 한스 루돌프 하우스, 헨리테 브룬너, 베아트리체 귄터 기질 분해 메탈로프로테이나제를 억제하는 술포닐아미노유도체
US6329418B1 (en) * 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU4074799A (en) 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Substituted aryl hydroxamic acids as metalloproteinase inhibitors
JP2002516904A (ja) 1998-06-03 2002-06-11 ジーピーアイ ニル ホールディングス インコーポレイテッド Ｎ−複素環式カルボン酸またはカルボン酸等配電子体のｎ−結合スルホンアミド
JP2002518368A (ja) 1998-06-17 2002-06-25 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての環式ヒドロキサム酸類
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
JP2000127349A (ja) * 1998-08-21 2000-05-09 Komori Corp 凹版印刷機
JP2002523492A (ja) 1998-08-29 2002-07-30 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド タンパク質分解酵素阻害剤としてのヒドロキサム酸誘導体
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
DE69907238T2 (de) 1998-10-07 2003-11-06 Yazaki Corp Sol-gel verfahren unter verwendung poröser formen
DK1004578T3 (da) * 1998-11-05 2004-06-28 Pfizer Prod Inc 5-oxo-pyrrolidin-2-carboxylsyrehydroxamidderivater
EA200100675A1 (ru) 1998-12-18 2001-12-24 Аксис Фармасьютикалз, Инк. Ингибиторы протеазы
EP1150975A1 (en) * 1998-12-31 2001-11-07 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
WO2000044770A1 (fr) 1999-01-28 2000-08-03 Chugai Seiyaku Kabushiki Kaisha Derives phenethylamine substitues
US6294694B1 (en) 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US20020006920A1 (en) 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
US6266453B1 (en) 1999-07-26 2001-07-24 Computerized Medical Systems, Inc. Automated image fusion/alignment system and method
DE60026404T2 (de) * 1999-08-02 2006-10-19 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von Benzothiophen-Derivaten
EA005373B1 (ru) 1999-08-12 2005-02-24 Фармация Италия С.П.А. Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств
JP3710964B2 (ja) 1999-08-26 2005-10-26 富士通株式会社 ディスプレイデバイスのレイアウト設計方法
SE9904044D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
WO2002014262A1 (fr) 2000-08-11 2002-02-21 Kaken Pharmaceutical Co.,Ltd. Derives de l'acide 2,3-diphenylpropionique ou leurs sels, medicaments ou inhibiteurs d'adhesion cellulaire en contenant, et leur utilisation
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
WO2002020515A1 (en) 2000-09-08 2002-03-14 Abbott Laboratories Oxazolidinone antibacterial agents
US20020091107A1 (en) * 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
BR0208105A (pt) 2001-03-15 2004-03-09 Astrazeneca Ab Inibidores de metaloproteinase
SE0100903D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) * 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2447475A1 (en) 2001-05-25 2002-12-05 Chu-Biao Xue Hydantion derivatives as inhibitors of matrix metalloproteinases
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
KR20050010826A (ko) 2002-06-05 2005-01-28 가부시키가이샤 가네카 광학 활성 α-메틸시스테인 유도체의 제조 방법
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
SE0202692D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
SE0202693D0 (sv) 2002-09-11 2002-09-11 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US6890913B2 (en) * 2003-02-26 2005-05-10 Food Industry Research And Development Institute Chitosans
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) * 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7648992B2 (en) * 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0403086D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20110003853A1 (en) 2011-01-06
PL365099A1 (en) 2004-12-27
CN101602731A (zh) 2009-12-16
CA2440631A1 (en) 2002-09-26
EP1370556A1 (en) 2003-12-17
CN1509276A (zh) 2004-06-30
NO20034042D0 (no) 2003-09-12
SK287834B6 (sk) 2011-12-05
HUP0400327A3 (en) 2005-06-28
ES2267986T3 (es) 2007-03-16
HUP0400327A2 (hu) 2005-01-28
RU2285695C2 (ru) 2006-10-20
IL157656A (en) 2010-11-30
IS6946A (is) 2003-09-10
NO20034044D0 (no) 2003-09-12
CN1269804C (zh) 2006-08-16
KR100879905B1 (ko) 2009-01-21
CA2440473A1 (en) 2002-09-26
US7754750B2 (en) 2010-07-13
US7427631B2 (en) 2008-09-23
CZ20032497A3 (cs) 2004-02-18
CN1509272A (zh) 2004-06-30
ZA200306731B (en) 2004-11-29
KR20030082986A (ko) 2003-10-23
DK1370556T3 (da) 2006-10-30
JP2010077137A (ja) 2010-04-08
KR20030082987A (ko) 2003-10-23
HK1060121A1 (en) 2004-07-30
DE60238794D1 (de) 2011-02-10
IL157652A0 (en) 2004-03-28
AU2002237626B2 (en) 2007-05-17
WO2002074748A1 (en) 2002-09-26
CN1304377C (zh) 2007-03-14
DE60213216D1 (en) 2006-08-31
MY136141A (en) 2008-08-29
BR0207983A (pt) 2004-06-15
NZ528140A (en) 2005-02-25
CN1509286A (zh) 2004-06-30
NZ528106A (en) 2005-03-24
MXPA03008181A (es) 2003-12-12
NO20034042L (no) 2003-11-10
EP1370537A1 (en) 2003-12-17
HUP0400194A2 (hu) 2004-07-28
ATE484496T1 (de) 2010-10-15
AR035695A1 (es) 2004-06-23
US8153673B2 (en) 2012-04-10
PL364706A1 (en) 2004-12-13
NO326087B1 (no) 2008-09-15
CA2440473C (en) 2011-08-30
RU2003127733A (ru) 2005-03-20
ZA200306732B (en) 2004-11-29
CN1962641A (zh) 2007-05-16
HUP0400202A3 (en) 2004-10-28
US7666892B2 (en) 2010-02-23
UA77667C2 (en) 2007-01-15
JP5140058B2 (ja) 2013-02-06
NO20034044L (no) 2003-11-10
CA2440630A1 (en) 2002-09-26
SK10962003A3 (sk) 2004-03-02
EE200300445A (et) 2003-12-15
UA78502C2 (en) 2007-04-10
HUP0400202A2 (hu) 2004-08-30
AR035443A1 (es) 2004-05-26
WO2002074767A1 (en) 2002-09-26
PT1370556E (pt) 2006-11-30
MY136789A (en) 2008-11-28
ATE493406T1 (de) 2011-01-15
EP1676846A3 (en) 2006-07-26
ZA200306737B (en) 2004-11-29
EE200300449A (et) 2003-12-15
AU2002237632B2 (en) 2007-05-10
RU2293729C2 (ru) 2007-02-20
KR20080071210A (ko) 2008-08-01
IS6942A (is) 2003-09-09
CN1962641B (zh) 2012-07-04
WO2002074748A8 (en) 2004-04-22
US20080262045A1 (en) 2008-10-23
WO2002074767A8 (en) 2004-04-22
NO20034045L (no) 2003-11-10
KR20030082989A (ko) 2003-10-23
IS6943A (is) 2003-09-09
SK10952003A3 (sk) 2004-05-04
RU2003127734A (ru) 2005-03-20
PL205315B1 (pl) 2010-04-30
NO20034045D0 (no) 2003-09-12
SK10922003A3 (sk) 2004-05-04
EP1370534A1 (en) 2003-12-17
BR0208104A (pt) 2004-03-02
JP2004523583A (ja) 2004-08-05
BR0207984A (pt) 2004-06-15
KR100886315B1 (ko) 2009-03-04
DE60213216T2 (de) 2007-07-12
US20100273849A1 (en) 2010-10-28
WO2002074751A1 (en) 2002-09-26
US7368465B2 (en) 2008-05-06
US7625934B2 (en) 2009-12-01
IL157652A (en) 2010-11-30
US20040127528A1 (en) 2004-07-01
UA77408C2 (en) 2006-12-15
ES2352246T3 (es) 2011-02-16
JP4390457B2 (ja) 2009-12-24
US20040138276A1 (en) 2004-07-15
SE0100902D0 (sv) 2001-03-15
SK287766B6 (sk) 2011-09-05
NZ528107A (en) 2005-06-24
EP1676846B1 (en) 2010-12-29
PL364707A1 (en) 2004-12-13
US20080171882A1 (en) 2008-07-17
EP1370537B1 (en) 2010-10-13
RU2288228C2 (ru) 2006-11-27
HUP0400194A3 (en) 2004-10-28
CN100526307C (zh) 2009-08-12
CA2440630C (en) 2011-09-27
EE05364B1 (et) 2010-12-15
CZ20032500A3 (cs) 2004-02-18
ZA200306734B (en) 2004-11-29
HK1091492A1 (en) 2007-01-19
CZ20032499A3 (cs) 2004-03-17
MXPA03008191A (es) 2004-01-29
JP2004523581A (ja) 2004-08-05
US20080306065A1 (en) 2008-12-11
EP1676846A2 (en) 2006-07-05
RU2003127735A (ru) 2005-03-20
HK1059932A1 (en) 2004-07-23
ES2357138T3 (es) 2011-04-19
SI1370556T1 (sl) 2006-10-31
IL157657A0 (en) 2004-03-28
IL157656A0 (en) 2004-03-28
EP1370556B1 (en) 2006-07-19
MXPA03008177A (es) 2003-12-12
US20040106659A1 (en) 2004-06-03
JP2004527515A (ja) 2004-09-09
ATE333454T1 (de) 2006-08-15
DE60237965D1 (en) 2010-11-25
EE200300451A (et) 2003-12-15
NO327114B1 (no) 2009-04-27
CY1107525T1 (el) 2013-03-13

Similar Documents

Publication Publication Date Title
ATE484496T1 (de) Metalloproteinaseinhibitoren
EE200300439A (et) Metalloproteinaasi inhibiitorid
EE200300450A (et) Metalloproteinaasi inhibiitorid
DE60234125D1 (de) E inhibitoren
CY2015028I2 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
PT1370553E (pt) Inibidores de rhoquinase
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
DE60218138D1 (de) Rho-kinase inhibitoren
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
NO20033570L (no) Pyridin-matriks-metalloproteinase-inhibitorer
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20025786D0 (no) Protaseinhibitorer
NO20025005D0 (no) Proteaseinhibitorer
NO20032328D0 (no) Proteaseinhibitorer
SE0100694D0 (sv) DHFR inhibitors

Legal Events

Date Code Title Description
MM4A Lapsed by not paying the annual fees

Effective date: 20130313